Corporate Connect has published a research report on Antisense Therapeutics:
Sarepta Therapeutics’ (NASDAQ: SRPT) SRP-9001, a putative gene therapy (GT) for all Duchenne muscular dystrophy (DMD) patients has failed to demonstrate an improvement clinical function in a double- blind, randomised, placebo-controlled phase II trial in 41 patients. This event significantly improves the commercial prospects Antisense Therapeutics’ DMD therapy, ATL1102.
